Post consolidation therapy for adult patients with acute myeloid leukaemia.
AuthorsRanson, Malcolm R
Scarffe, J Howard
Morgenstern, Godfrey R
Deakin, David P
Ryder, W David J
AffiliationDepartment of Medical Oncology, CRC University of Manchester.
MetadataShow full item record
AbstractOne hundred and sixteen adult patients aged 14-73 with previously untreated acute myeloid leukaemia received induction and consolidation chemotherapy with daunorubicin, cytosine arabinoside and thioguanine. Two novel approaches to post consolidation therapy have been investigated. Patients aged 50 years or less who had no suitable matched allogeneic donor were considered for autologous bone marrow transplantation (BMT) using bone marrow which had been cultured in vitro for 14 d. Patients over the age of 50 years with normal bone marrow cellularity and peripheral blood count were treated with a single oral dose of busulphan 100 mg/m2 (without BMT rescue) 3 months following the completion of consolidation therapy. Eighty-seven patients (75%) achieved a complete remission. Of 70 patients who completed consolidation therapy, 40 were aged less than or equal to 50 years and 30 were greater than 50 years. Forty-three patients went on to receive post consolidation therapy in first CR (autologous BMT 12, allogeneic BMT 7, busulphan therapy 24). The event-free survival at 4 years was 47% for autologous BMT, 34% for allogeneic BMT and 45% for busulphan-treated patients. The survival for the older cohort of patients who received post consolidation therapy with single dose busulphan therapy was encouraging, and this agent should be considered for future post consolidation strategies.
CitationPost consolidation therapy for adult patients with acute myeloid leukaemia. 1991, 79 (2):162-9 Br. J. Haematol.
JournalBritish Journal of Haematology
- [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
- Authors: Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G
- Issue date: 1996 Apr 12
- Varying intensity of postremission therapy in acute myeloid leukemia.
- Authors: Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ
- Issue date: 1992 Apr 15
- Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
- Authors: Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, Francois S, Briere J, Guyotat D, Casassus P, Audhuy B, Tellier Z, Hurteloup P, Herve P
- Issue date: 1997 Oct 15
- A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
- Authors: Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M
- Issue date: 1996 Oct 15
- Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission.
- Authors: Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H
- Issue date: 1993 Dec 15